TheBodyPro | Expert analysis from Benjamin Young, M.D., Ph.D.
Most anal high-grade squamous intraepithelial lesions (HSIL) will regress without treatment, according to recently published study results from a cohort of French men who are living with HIV and who have sex with other men (MSM). The findings provide us with important nuance in the wake of the guideline-changing ANCHOR study, and hopefully will reignite a conversation about how best to approach anal cancer screening and treatment in patients living with HIV.
Key Takeaways
- In a cohort of MSM living with HIV, 75% of untreated anal hHSIL cases regressed within five years, with no anal cancers occurring during 300 person-years of follow-up.
- Several factors — including persistent HPV-16, HSIL cytology, and host cell DNA methylation markers — were associated with a greater likelihood of lesion persistence.
- The findings support improving anal HSIL risk stratification, not abandoning treatment, and normalizing conversations about anal health within all subpopulations of patients with HIV.
Read the full analysis here.
Source : TheBodyPro
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.